The content on this site is intended for healthcare professionals only
Dr Cristina Saura speaks to ecancer in an online interview as part of the ESMO 2021 meeting about the primary outcomes of the TULIP trial.
She explains that the trial compared [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer.
Dr Saura reports that this treatment showed improvement in progression-free survival over physician’s choice treatment, and discusses the adverse events experienced.
Read more about the study here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors
Key insights from lung cancer research at ASCO 2025
ELCC 2025: Latest in EGFR positive NSCLC
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Latest in EGFR mutated NSCLC
Hormonal receptor positive breast cancer adjuvant and metastatic indications
